Add to ORKGDisclosures of potential conflicts of interest may be found at the end of this article. Key Words. ERCC1 x Tumor predictive biomarker x Platinum sensitivity x Lung cancer Introduction. Excision repair cross-complementation group 1 (ERCC1) expression by non-small cell lung cancer (NSCLC) has been reported to predict resistance to platinum-based therapies. On this basis, several commercial laboratories have offered ERCC1 testing to facilitate clinical decisionmaking, bu
Objective: “Excision Repair Cross-Complementation Group 1” (ERCC1) enzyme is a vitally important bas...
Despite discrepant results on clinical utility, several trials are already prospectively randomizing...
Despite discrepant results on clinical utility, several trials are already prospectively randomizing...
Disclosures of potential conflicts of interest may be found at the end of this article. Key Words. E...
Although platinum-based chemotherapy remains the “standard” in advanced non small-cell lung cancer, ...
The identification of novel prognostic markers may help to better assess survival probability in dif...
Purpose Retrospective studies indicate that expression of excision repair cross complementing group ...
The goal of this study is to determine role of excision repair cross-complementing group 1 gene (ERC...
Excision Repair Cross-Complementing Group 1 (ERCC1) is an important DNA repair gene, playing critica...
Excision Repair Cross-Complementing Group 1 (ERCC1) is an important DNA repair gene, playing critica...
Full list of author information is available at the end of the articleBackground The current standar...
There is growing interest in defining biomarkers that could predict response to different chemothera...
BackgroundPlatinum-based therapy is pivotal to the treatment of advanced non-small cell lung Cancer ...
Objective. To carry out the meta-analysis on the relationship between the expression of nucleotide e...
Purpose: The excision repair cross-complementation 1 (ERCC1) enzyme plays a rate-limiting role in th...
Objective: “Excision Repair Cross-Complementation Group 1” (ERCC1) enzyme is a vitally important bas...
Despite discrepant results on clinical utility, several trials are already prospectively randomizing...
Despite discrepant results on clinical utility, several trials are already prospectively randomizing...
Disclosures of potential conflicts of interest may be found at the end of this article. Key Words. E...
Although platinum-based chemotherapy remains the “standard” in advanced non small-cell lung cancer, ...
The identification of novel prognostic markers may help to better assess survival probability in dif...
Purpose Retrospective studies indicate that expression of excision repair cross complementing group ...
The goal of this study is to determine role of excision repair cross-complementing group 1 gene (ERC...
Excision Repair Cross-Complementing Group 1 (ERCC1) is an important DNA repair gene, playing critica...
Excision Repair Cross-Complementing Group 1 (ERCC1) is an important DNA repair gene, playing critica...
Full list of author information is available at the end of the articleBackground The current standar...
There is growing interest in defining biomarkers that could predict response to different chemothera...
BackgroundPlatinum-based therapy is pivotal to the treatment of advanced non-small cell lung Cancer ...
Objective. To carry out the meta-analysis on the relationship between the expression of nucleotide e...
Purpose: The excision repair cross-complementation 1 (ERCC1) enzyme plays a rate-limiting role in th...
Objective: “Excision Repair Cross-Complementation Group 1” (ERCC1) enzyme is a vitally important bas...
Despite discrepant results on clinical utility, several trials are already prospectively randomizing...
Despite discrepant results on clinical utility, several trials are already prospectively randomizing...